Dexlansoprazole
Mechanism :
Proton pump inhibitor; decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system.
Indication :
Contraindications :
Known hypersensitivity to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.
Dosing :
≥12 years of age.
GERD:
30 mg once daily for 4 weeks orally.
Erosive esophagitis:
Healing: 60 mg once daily for up to 8 weeks,
Maintenance: 30 mg orally once daily for upto 16 weeks.
Adverse Effect :
Abdominal pain, diarrhea, flatulence, abdominal distress and tenderness, Barrett esophagus, angina pectoris, bradycardia, arrhythmias, chest pain, DVT, hypertension, headache, dizziness, falling, psychomotor agitation, anemia, thrombocytopenia, abnormal hepatic functions tests.
Interaction :
Clopidogrel: Dexlansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.
Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.
Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.
Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.
Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole.
Hepatic Dose :
Mild hepatic impairment: No dose adjustment required.
Moderate hepatic impairment: Do not use more than 30 mg PO daily.
Severe hepatic impairment: Avoid use.